5.08
-0.2(-3.79%)
Currency In USD
Address
100 Campus Drive
Florham Park, NJ 07932
United States of America
Phone
608 441 8120
Website
Sector
Healthcare
Industry
Biotechnology
Employees
11
First IPO Date
November 10, 2005
| Name | Title | Pay | Year Born |
| Mr. James V. Caruso | President, Chief Executive Officer & Director | 828,750 | 1959 |
| Mr. Chad J. Kolean CPA | Vice President, Chief Financial Officer & Secretary | 510,000 | 1964 |
| Mr. Jarrod Longcor | Chief Operating Officer | 600,000 | 1973 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.